Quote this publication Share Print

KOMBOGLYZE

-
Opinions on drugs - Posted on Jun 10 2013

Reason for request

Extension of indication

-


Actual benefit

Faible

Low, and provisional pending re-evaluation of gliptins in triple therapy, in combination with insulin when combined insulin/metformin, with diet and exercise, does not provide adequate glycaemic control.


Improvement in actual benefit

V (absence)

In triple therapy in combination with insulin, KOMBOGLYZE, a fixed-dose combination of saxagliptin and metformin, does not offer any improvement in actual benefit (IAB V, non-existent) in the treatment of patients with type 2 diabetes in whom combined insulin/metformin, with diet and exercise, does not provide adequate glycaemic control.


Contact Us

Évaluation des médicaments

See also